DrugPatentWatch Database Preview
REYVOW Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Reyvow patents expire, and what generic alternatives are available?
Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.
This drug has forty patent family members in thirty countries.
The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
US ANDA Litigation and Generic Entry Outlook for Reyvow
Reyvow will be eligible for patent challenges on January 31, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 6, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for REYVOW
| International Patents: | 40 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 52 |
| Patent Applications: | 17 |
| Drug Prices: | Drug price information for REYVOW |
| DailyMed Link: | REYVOW at DailyMed |
Generic Entry Opportunity Date for REYVOW
Generic Entry Date for REYVOW*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for REYVOW
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for REYVOW
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ukraine | 77504 | Start Trial |
| Germany | 60308850 | Start Trial |
| Eurasian Patent Organization | 200401282 | Start Trial |
| Hong Kong | 1073464 | Start Trial |
| Israel | 163928 | Start Trial |
| Japan | 4493345 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
